I1 Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Barac, Yaron D ^a   Bar Am, Orit ^a   Liani, Esti ^a   Amit, Tamar ^a   Frolov, Luba ^a   Ovcharenko, Elena ^a   Angel, Itzchak ^b   Youdim, Moussa B H ^a   Binah, Ofer ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b APCT Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; EFAROXAN; IDAZOXAN; IMIDAZOLINE I1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MOXONIDINE; PROTEIN P42; PROTEIN P44; RASAGILINE; RILMENIDINE; BENZOFURAN DERIVATIVE; CARDIOTONIC AGENT; IMIDAZOLE DERIVATIVE; IMIDAZOLINE I1 RECEPTORS; IMIDAZOLINE RECEPTOR; INDAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENANTIOMER; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOREACTIVITY; NEWBORN; NONHUMAN; PHEOCHROMOCYTOMA CELL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IC 50; IN VITRO STUDY; METABOLISM; PC12 CELL; SIGNAL TRANSDUCTION;

RATTUS;

ANIMALS; BENZOFURANS; BINDING SITES; BLOTTING, WESTERN; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; IMIDAZOLINE RECEPTORS; INDANS; INHIBITORY CONCENTRATION 50; MITOGEN-ACTIVATED PROTEIN KINASE 1; MYOCYTES, CARDIAC; PC12 CELLS; RATS; SIGNAL TRANSDUCTION;

EID: 84869206960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047890     Document Type: Article

References (29)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, et al. (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: 480-486.
2. Tiyyagura SR, Pinney SP, (2006) Left ventricular remodeling after myocardial infarction: past, present, and future. Mt Sinai J Med 73: 840-851.
3. Downey JM, Cohen MV, (2009) Why do we still not have cardioprotective drugs? Circ J 73: 1171-1177.
4. Black SC, (2000) In vivo models of myocardial ischemia and reperfusion injury: application to drug discovery and evaluation. J Pharmacol Toxicol Methods 43: 153-167.
5. Huang W, Chen Y, Shohami E, Weinstock M, (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. European Journal of Pharmacology 366: 127-135.
6. Mandel S, Weinreb O, Amit T, Youdim MB, (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48: 379-387.
7. Naoi M, Maruyama W, (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 9: 1233-1250.
8. Youdim MBH, Gross A, Finberg JPM, (2001) Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology. 132: 500-506.
9. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, et al. (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79: 172-179.
10. Weinreb O, Amit T, Bar-Am O, Youdim MB, (2010) Rasagiline; a Novel Anti-Parkinsonian Monoamine Oxidase-B Inhibitor with Neuroprotective Activity. Prog Neurobiol 92: 330-344.
11. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH, (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18: 1471-1473.
12. Kleiner Y, Bar-Am O, Amit T, Berdichevski A, Liani E, et al. (2008) TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. J Cardiovasc Pharmacol 52: 268-277.
13. Ertracht O, Liani E, Bachner-Hinenzon N, Bar-Am O, Frolov L, et al. (2011) The cardioprotective efficacy of TVP1022 in a rat model of ischemia/reperfusion. Br J Pharmacol doi: 10.1111/j.1476-5381.2011.01274.x.
14. Berdichevski A, Meiry G, Milman F, Reiter I, Sedan O, et al. (2010) TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements. J Pharmacol Exp Ther 332: 413-420.
15. Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S, (2010) Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 21: 361-371.
16. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, et al. (2001) The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 79: 931-940.
17. Edwards L, Ernsberger P, (2003) The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase. Brain Res 980: 71-79.
18. Dupuy L, Urosevic D, Greney H, Quaglia W, Pigini M, et al. (2004) I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. Cell Death Differ 11: 1049-1052.
19. Musgrave IF, Hughes RA, (1999) Novel targets and techniques in imidazoline receptor research. Ann N Y Acad Sci 881: 301-312.
20. Separovic D, Kester M, Ernsberger P, (1996) Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 49: 668-675.
21. Molderings GJ, Bonisch H, Hammermann R, Gothert M, Bruss M, (2002) Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem Int 40: 157-167.
22. Molderings GJ, Bonisch H, Bruss M, Wolf C, von Kugelgen I, et al. (2007) S1P-receptors in PC12 and transfected HEK293 cells: molecular targets of hypotensive imidazoline I(1) receptor ligands. Neurochem Int 51: 476-485.
23. Sugiyama A, Aye NN, Yatomi Y, Ozaki Y, Hashimoto K, (2000) Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system. Jpn J Pharmacol 82: 338-342.
24. Zhang J, El-Mas MM, Abdel-Rahman AA, (2001) Imidazoline I(1) receptor-induced activation of phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells. Eur J Pharmacol 415: 117-125.
25. Separovic D, Kester M, Haxhiu MA, Ernsberger P, (1997) Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 749: 335-339.
26. Ernsberger P, (1999) The I1-imidazoline receptor and its cellular signaling pathways. Ann N Y Acad Sci 881: 35-53.
27. Stabile AM, Aceros H, Stockmeyer K, Abdel Rahman AA, Noiseux N, et al. (2011) Functional and molecular effects of imidazoline receptor activation in heart failure. Life Sci 88: 493-503.
28. Molderings GJ, Moura D, Fink K, Bonisch H, Gothert M, (1993) Binding of [3H]clonidine to I1-imidazoline sites in bovine adrenal medullary membranes. Naunyn Schmiedebergs Arch Pharmacol 348: 70-76.
29. Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT, (1990) Alpha 2-adrenoceptor subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol 99: 803-809.